Translational strategies for cancer prevention in liver (original) (raw)
Parkin, D. M., Pisani, P. & Ferlay, J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer80, 827–841 (1999). CASPubMed Google Scholar
Li, L. & Rao, K. (eds) Cancer Incidence and Mortality in Cities and Counties of P. R. China 1988–1992 (China Medical Science and Technology Press, 2001). Google Scholar
Jemel, A. et al. Cancer statistics 2003. CA Cancer J. Clin.53, 5–26 (2003). Google Scholar
World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition and the Prevention of Cancer: a Global Perspective (American Institute for Cancer Research, Washington DC, 1997).
Chen, J. -G. et al. Population-based cancer survival in Qidong, People's Republic of China. IARC Sci. Publ.145, 27–35 (1998). Google Scholar
Merican, I. et al. Chronic hepatitis B virus infection in Asian countries. J. Gastroenterol. Hepatol.15, 1356–1361 (2000). CASPubMed Google Scholar
Ogunbiyi, J. O. Hepatocellular carcinoma in the developing world. Semin. Oncol.28, 179–187 (2001). CASPubMed Google Scholar
Aflatoxins. IARC Monograph on the Evaluation of Carcinogenic Risks to Humans82, 171–300 (2002).
Hahn, W. C. & Weinberg, R. A. Modeling the molecular circuitry of cancer. Nature Rev. Cancer2, 331–341 (2002). CAS Google Scholar
Vogelstein, B. & Kinzler, K. W. (eds) The Genetic Basis of Human Cancer 2nd edn (McGraw–Hill, New York, 2002). Google Scholar
Herman, J. G. Hypermethylation pathways to colorectal cancer. Implications for prevention and detection. Gastroenterol. Clin. North Am.31, 945–958 (2002). PubMed Google Scholar
Thorgeirsson, A. & Grisham, J. W. Molecular pathogenesis of human hepatocellular carcinoma. Nature Genet.31, 339–346 (2002). CASPubMed Google Scholar
Hoofnagle, J. H. & Schafer, D. F. Serologic markers of hepatitis B virus infection. Semin. Liver Dis.6, 1–10 (1986). CASPubMed Google Scholar
Weiland, O. & Schvarcz, R. Hepatitis C: virology, epidemiology, clinical course, and treatment. Scand. J. Gastroenterol.27, 337–342 (1992). CASPubMed Google Scholar
Plaa, G. L. & Hewitt, W. R. in Principles and Methods of Toxicology 2nd edn (ed. Hayes, A. W.) 599–628 (Raven Press, New York, 1989). Google Scholar
Colombo, M. Hepatitis C virus and hepatocellular carcinoma. Baillière's Clin. Gastroenterol.13, 519–528 (1999). CAS Google Scholar
El-Serag, H. B. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology36, S75–S83 (2002). Google Scholar
Zein, C. O. & Zein, N. N. Advances in therapy for hepatitis C infection. Microbes Infect.4, 1237–1246 (2002). CASPubMed Google Scholar
Essigmann, J. M. et al. Structural identification of the major DNA adduct formed by aflatoxin B1 in vitro. Proc. Natl Acad. Sci. USA74, 1870–1874 (1977). CASPubMedPubMed Central Google Scholar
Sabbioni, G., Skipper, P. L., Büchi, G. & Tannenbaum, S. R. Isolation and characterization of the major serum albumin adduct formed by aflatoxin B1 in vivo in rats. Carcinogenesis8, 819–824 (1987). CASPubMed Google Scholar
Bennett, R. A., Essigmann, J. M. & Wogan, G. N. Excretion of an aflatoxin–guanine adduct in the urine of aflatoxin B1-treated rats. Cancer Res.41, 650–654 (1981). CASPubMed Google Scholar
Ross, R. K. et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet339, 943–946 (1992). This study was the first to show the synergistic interaction between aflatoxin exposure and infection with hepatitis B virus (HBV) in the aetiology of hepatocellular carcinoma (HCC). CASPubMed Google Scholar
Qian, G. -S. et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer in Shanghai, People's Republic of China. Cancer Epidemiol. Biomarkers Prev.3, 3–10 (1994). CASPubMed Google Scholar
Sun, Z. -T. et al. Increased risk of hepatocellular carcinomain male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. . Hepatology30, 379–383 (1999). CASPubMed Google Scholar
Wang, L. -Y. et al. Aflatoxin exposure and the risk of hepatocellular carcinoma in Taiwan. Int. J. Cancer67, 620–625 (1996). CASPubMed Google Scholar
Yu, M. W. et al. Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. J. Hepatol.27, 320–330 (1997). CASPubMed Google Scholar
Okuda, K. Clinical and public health challenges of cancer. Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants. J. Gastroenterol. Hepatol.17, 401–405 (2002). PubMed Google Scholar
Johnson, P. J. The role of serum α-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin. Liver Dis.5, 145–159 (2001). CASPubMed Google Scholar
Chen, J. -G. et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J. Med. Screening (in the press).
Kim, J. W. & Wang, X. W. Gene expression profiling of preneoplastic liver disease and liver cancer: a new era for improved early detection and treatment of these deadly diseases? Carcinogenesis24, 363–369 (2003). CASPubMed Google Scholar
Nawroz, H. et al. Microsatellite alterations in serum DNA of head and neck cancer patients. Nature Med.2, 1035–1037 (1996). CASPubMed Google Scholar
Yamada, T. et al. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin. Cancer Res.4, 1527–1532 (1998). CASPubMed Google Scholar
Esteller, M. et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res.59, 67–70 (1999). CASPubMed Google Scholar
Wong, I. H. et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res.59, 71–73 (1999). CASPubMed Google Scholar
Anker, P., Mulcahy, H., Chen, X. Q. & Stroun, M. Detection of circulating tumor DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev.18, 65–73 (1999). CASPubMed Google Scholar
Wong, I. H., Lo, Y. M., Yeo, W., Lau, W. Y. & Johnson, P. J. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin. Cancer Res.6, 3516–3521 (2000). CASPubMed Google Scholar
Zhong, S. et al. Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. Clin. Cancer Res.8, 1087–1092 (2002). Epigenetic silencing of a gene encoding a carcinogen-detoxification enzyme, GSTP1, is associated with the pathogenesis of HCC. CASPubMed Google Scholar
Hsia, C. C., Yowen, H. & Tabor, E. Hot-spot mutations in hepatitis B virus X gene in hepatocellular carcinoma. Lancet348, 625–626 (1996). CASPubMed Google Scholar
Ming, L. et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology36, 1214–1220 (2002). A comprehensive assessment of the separate and combined effects of HBV, hepatitis C virus (HCV) and aflatoxin in causing HCC in Qidong, China. CASPubMed Google Scholar
Kuang, S. -Y. et al. Detection of specific mutations in the hepatitis B virus X-gene associated with codon 249 mutations in p53 in hepatocellular carcinoma patients. Proc. Am. Assoc. Cancer Res.44, 593 (2003). Google Scholar
Wang, X. W. et al. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology181–182, 43–47 (2002). PubMed Google Scholar
Wild, C. P. & Turner, P. C. The toxicology of aflatoxins as a basis for public health decisions. Mutagenesis17, 471–481 (2002). CASPubMed Google Scholar
Staib, F. et al. TP53 and liver carcinogenesis. Hum. Mutat.21, 201–216 (2003). CASPubMed Google Scholar
Kirk, G. D. et al. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J. Natl Cancer Inst.92, 148–153 (2000). The first demonstration that mutations of TP53 can be detected in plasma samples of patients with HCC. CASPubMed Google Scholar
Jackson, P. E. et al. Specific p53 mutation detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res.61, 33–35 (2001). CASPubMed Google Scholar
Jackson, P. E. et al. Prospective detection of codon 249 mutations in p53 in plasma of hepatocellular carcinoma patients. Carcinogenesis (in the press).
Wild, C. P. & Turner, P. C. in Biomarkers in Cancer Chemoprevention (eds Miller, A. B. et al.) 154, 215–222 (International Agency for Research on Cancer by Oxford University Press, UK, 2001). Google Scholar
Sun, T. -T. et al. A pilot study on universal immunization of newborn infants in an area of hepatitis B virus and primary hepatocellular carcinoma prevalence with a low dose of hepatitis B vaccine. J. Cell. Physiol.4, 83–90 (1986). CAS Google Scholar
Chang, M. -H. et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med.336, 1855–1859 (1997). The initial report describing the efficacy of HBV vaccination in reducing the incidence of HCC. CASPubMed Google Scholar
Lee, C. -L., Hsieh, K. -S. & Ko, Y. -C. Trends in the incidence of hepatocellular carcinoma in boys and girls in Taiwan after large-scale hepatitis B vaccination. Cancer Epidemiol. Biomarkers Prev.12, 57–59 (2003). CASPubMed Google Scholar
Busby, W. F. Jr & Wogan, G. N. in Chemical Carcinogenesis 2nd edn, Vol. 2 (ed. Searle, C. E.) 945–1136 (ACS, Washington DC, 1984). Google Scholar
Turner, P. C. et al. The role of aflatoxins and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: a basis for primary prevention in Guinea-Conakry, West Africa. J. Gastroenterol. Hepatol.17, S441–S448 (2002). This study describes the development and use of biomarkers to assess the impact of reduction of aflatoxin exposure on the development of HCC in high-risk populations. PubMed Google Scholar
Sporn, M. B. & Suh, N. Chemoprevention: an essential approach to controlling cancer. Nature Rev. Cancer2, 537–543 (2002). CAS Google Scholar
Gupta, R. A. & DuBois, R. N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nature Rev. Cancer1, 11–21 (2001). CAS Google Scholar
Dashwood, R. et al. Chemopreventive properties of chlorophylls towards aflatoxin B1. A review of the antimutagenicity and anticarcinogenicity data in rainbow trout. Mutat. Res.399, 245–253 (1998). CASPubMed Google Scholar
Kephart, J. C. Chlorophyll derivatives — their chemistry, commercial preparation and uses. Econ. Bot.9, 3–38 (1955). CAS Google Scholar
Young, R. W. & Bergei, J. S. Use of chlorophyllin in the care of geriatric patients. J. Am. Geriat. Soc.24, 46–47 (1980). Google Scholar
Breinholt, V., Schimerlik, M., Dashwood, R. & Bailey, G. Mechanisms of chlorophyllin anticarcinogenesis against aflatoxin B1. Complex formation with the carcinogen. Chem. Res. Toxicol.8, 506–514 (1995). CASPubMed Google Scholar
Egner, P. A. et al. Chlorophyllin intervention reduces aflatoxin–DNA adducts in individuals at high risk for liver cancer. Proc. Natl Acad. Sci. USA98, 14601–14606 (2001). A pivotal clinical trial showing that an 'interceptor' molecule, chlorophyllin, can be used to reduce the bioavailability of aflatoxin in humans. CASPubMedPubMed Central Google Scholar
Bergquist, N. R. Schistosomiasis: from risk assessment to control. Trends Parasitol.18, 309–314 (2002). PubMed Google Scholar
Wang, J. -S. et al. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J. Natl Cancer Inst.91, 347–354 (1999). This study showed that oltipraz can modulate the effects of aflatoxin in humans through the induction of carcinogen-detoxification enzymes. CASPubMed Google Scholar
Kensler, T. W. et al. Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. Cancer Epidemiol. Biomarkers Prev.7, 127–134 (1998). CASPubMed Google Scholar
Talalay, P. & Talalay, P. The importance of using scientific principles in the development of medicinal agents from plants. Acad. Med.76, 238–247 (2001). CASPubMed Google Scholar
Fahey, J. W., Zalcmann, A. T. & Talalay, P. The chemical diversity and distribution of glucosinolates and isothiocyanates among plants. Phytochemistry56, 5–51 (2001). CASPubMed Google Scholar
Zhang, Y., Talalay, P., Cho, C. G. & Posner, G. H. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc. Natl Acad. Sci. USA89, 2399–2403 (1992). CASPubMedPubMed Central Google Scholar
Fahey, J. W., Zhang, Y. & Talalay, P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc. Natl Acad. Sci. USA94, 10367–10372 (1997). The initial demonstration that high levels of the anti-carcinogen isothiocyanate sulphoraphane can be found in 3-day-old broccoli sprouts. CASPubMedPubMed Central Google Scholar
Shapiro, T. et al. Chemoprotective glucosinolates and isothiocyanates of broccoli sprouts: metabolism and excretion in humans. Cancer Epidemiol. Biomarkers Prev.10, 501–508 (2001). CASPubMed Google Scholar
Bogaards, J. J., Verhagen, H., Willems, M. I., van Poppel, G. & van Bladdern, P. J. Consumption of Brussels sprouts results in elevated α-class glutathione S-transferase levels in human blood plasma. Carcinogenesis15, 1073–1075 (1994). CASPubMed Google Scholar
Lampe, J. W. et al. Modulation of human glutathione S-transferases by botanically defined vegetable diets. Cancer Epidemiol. Biomarkers Prev.9, 787–793 (2000). CASPubMed Google Scholar
Primiano, T. et al. Intermittent dosing with oltipraz: relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases. Cancer Res.55, 4319–4324 (1995). CASPubMed Google Scholar
Nakachi, K., Matsuyama, S., Miyake, S., Suganuma, M. & Imai, K. Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. BioFactors13, 49–54 (2000). CASPubMed Google Scholar
Fujiki, H., Suganuma, M., Imai, K. & Nakachi, K. Green tea: cancer preventive beverage and/or drug. Cancer Lett.188, 9–13 (2002). CASPubMed Google Scholar
Wang, J. -S. et al. Chemoprevention trial of green tea polyphenols in high-risk population of liver cancer. Proc. Am. Assoc. Cancer Res.44, 1101 (2003). Google Scholar
Klaunig, J. E. et al. The effect of tea consumption on oxidative stress in smokers and nonsmokers. Proc. Soc. Exp. Biol. Med.220, 249–254 (1999). CASPubMed Google Scholar
Kang, K. W. et al. Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation. FASEB J.16, 1988–1990 (2002). CASPubMed Google Scholar
Muto, Y. et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma: hepatoma prevention study group. N. Engl. J. Med.334, 1561–1567 (1996). This study describes a clinical chemoprevention trial of polyprenoic acid in a Japanese cohort. HCV infection was the main cause of HCC in more than 70% of patients in the study population. Minimal side effects were reported for 600 mg of polyprenoic acid per day — a treatment that significantly prevented second primary tumours. CASPubMed Google Scholar
Okuno, M., Kojima, S. & Moriwaki, H. Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives. J. Gastroenterol. Hepatol.16, 1329–1335 (2001). CASPubMed Google Scholar
Lippman, S. M. & Hong, W. K. Cancer prevention by delay. Clin. Cancer Res.8, 305–313 (2002). PubMed Google Scholar
Kensler, T. W. et al. Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin–albumin adducts and risk of hepatocellular carcinoma. Cancer Epidemiol. Biomarkers Prev.6, 603–610 (1997). CASPubMed Google Scholar
Loeb, L. A., Loeb, K. A. & Anderson, J. P. Multiple mutations and cancer. Proc. Natl Acad. Sci. USA100, 776–781 (2003). CASPubMedPubMed Central Google Scholar
Sun, Z. & Zhu, Y. -R. Multifactorial etiology and multifaceted prevention strategy of hepatocellular carcinoma. Cancer Detect. Prev.14, 285–289 (1989). CASPubMed Google Scholar
Kensler, T. W., Groopman, J. D., Sutter, T. R., Curphey, T. J. & Roebuck, B. D. Development of cancer chemopreventive agents: oltipraz as a paradigm. Chem. Res. Toxicol.12, 113–126 (1999). CASPubMed Google Scholar
Kwak, M. -K. et al. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1–Nrf2 pathway. Identification of novel gene clusters for cell survival. J. Biol. Chem.278, 8135–8145 (2003). CASPubMed Google Scholar
Itoh, K. et al. A Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun.236, 313–322 (1997). CASPubMed Google Scholar
Itoh, K. et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev.13, 76–86 (1999). CASPubMedPubMed Central Google Scholar
Dinkova-Kostova, A. T. et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc. Natl Acad. Sci. USA99, 11908–11913 (2002). CASPubMedPubMed Central Google Scholar
Ramos-Gomez, M., Dolan, P. M., Itoh, K., Yamamoto, M. & Kensler, T. W. Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene–DNA adducts and tumor yield in mice. Carcinogenesis24, 461–467 (2003). CASPubMed Google Scholar
Ramos-Gomez, M. et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl Acad. Sci. USA98, 3410–3415 (2001). CASPubMedPubMed Central Google Scholar
Fahey, J. W. et al. Sulforaphane inhibits extracellular, intracellular, and antiobiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc. Natl Acad. Sci. USA99, 7610–7615 (2002). CASPubMedPubMed Central Google Scholar